V.M. Badiuk

V.M. Badiuk

Auto-generated profile, based on publicly available information

V.M. Badiuk

LLC ULTRAGENOME, Kyiv, Ukraine

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 April 2024 in INTERNATIONAL NEUROLOGICAL JOURNAL
Verified
Journal Article
Open access
PDF file
LKL.H. Kyrylova
L.H. Kyrylova
OMO.O. Miroshnykov
O.O. Miroshnykov
OYO.O. Yuzva
O.O. Yuzva
VBV.M. Badiuk
V.M. Badiuk
ODO.O. Dolenko
O.O. Dolenko
YBYu.M. Bondarenko
Yu.M. Bondarenko
Background. The purpose of the study to analyze the clinical, neurophysiological, neuroimaging and genetic characteristics of young children with developmental and epileptic encephalopathy and to determine risk predictors for the development of autism spectrum disorders, with the aim of forming a cohort of children in need of dynamic monitoring and early intervention. Materials and methods. Thirty-eight children aged 0–3 years with developmental and epileptic encephalopathy were included in the study. The examination included assessment of neurological status, history taking, assessment of semiology and determination of seizure type, assessment of development and screening for autism spectrum disorders at the age of 18 and 24 months, video-EEG monitoring during night sleep, magnetic resonance imaging of the brain, screening for pathogenic variants by whole exome sequen-cing. Results. A feature of this group of disorders is the presence of subtle, often unrecognized epileptic seizures, which are manifested by persistent focal (60.5 %) or generalized (31.6 %) activity with medium (55.3 %) or high (15.8 %) index of spike-and-wave activity during the stage of slow sleep and the amplitude emphasis over the frontal (52.6 %) or temporal (28.9 %) lobes. According to magnetic resonance imaging, structural changes in the brain were found in 91.1 % of children, including focal or diffuse changes in the white matter of the brain in 36.8 %, hypoplasia of the corpus callosum in 21.1 %, atrophic changes in the cerebral cortex in 15.8 %, congenital malformations in 13.2 % of cases. Pathogenic variants of 35 different genes were found in the examined children with the onset of seizures during the first year of life. Pathogenic variants of genes responsible for the synthesis and repair of DNA and RNA (28.9 %) and the activity of intracellular enzymes were the most common — 8 cases (21.1 %). The share of children with general developmental delay at the age of 24 months was 11.9 %, and cognitive impairment — 34.2 %. Conclusions. It was shown that children with a history of generalized tonic-clonic seizures (RR = 2.13) had a high risk of developing autism spectrum disorders at 24 months. A positive relationship was found between the presence of mutations in genes responsible for DNA synthesis and repair (RR = 1.88) and an increased risk of developing ASD at the age of 24 months (90.9 % of children).

24 September 2023 in UKRAINIAN JOURNAL OF PERINATOLOGY AND PEDIATRICS
Verified
Journal Article
Open access
PDF file
LKL.H. Kirilova
L.H. Kirilova
OMO.O. Miroshnikov
O.O. Miroshnikov
OBO.V. Beregela
O.V. Beregela
VBV.M. Badiuk
V.M. Badiuk
KUKyiv Llc Ultragenome
Kyiv Llc Ultragenome
YBY.M. Bondarenko
Y.M. Bondarenko
Today, genetic diagnosis methods are a powerful tool for a practicing doctor, which allows not only to establish the etiology of neurodevelopmental disorders in children, but also influences the further tactics of patient management, the choice of further diagnostic and therapeutic interventions, helps in predicting subsequent pregnancies for the family. Purpose - to analyze the information of modern specialized literature regarding the features of the use of modern cytogenetic methods of diagnosis, in particular, chromosomal micrometric analysis (СMA); give a clinical example of a child with a neurodevelopmental disorder and established chromosomal etiology. A review of the scientific literature regarding the advantages and features of using innovative methods of cytogenetic diagnostics (karyotyping, СMA), clinical manifestations of 2q13 microdeletion syndrome is given. A description of the clinical case of diagnosis of a child with 2q13 microdeletion syndrome is presented. A chromosomal micrometric analysis was performed, which revealed a heterozygous microdeletion on 2q13 with a size of 122 kilobases, which led to the loss of the NPHP1 and MALL genes. The obtained result of the CMA made it possible to optimize the tactics of monitoring the child, taking into account the increased risk of the development of kidney pathology and leukoencephalopathy, the recommended annual determination of the level of creatinine and urea in the blood, conducting an ultrasound of the kidneys and an MRI of the brain. Conclusions. The given clinical observation confirms the complexity of the diagnostic search for neurodevelopmental disorders in children. In children with autism spectrum disorder, developmental delay, intellectual disability, in the absence of epileptic seizures, regardless of the presence of dysmorphic facial features, it is recommended to begin the examination with CMA, and in children with epileptic encephalopathies, it is optimal to begin the examination with the next generation sequencing method (NGS), namely whole exome sequencing. The research was carried out in accordance with the principles of the Declaration of Helsinki. Informed consent of the children’s parents was obtained for the research. No conflict of interests was declared by the authors.

27 February 2026 in Modern pediatrics. Ukraine
Verified
Journal Article
Closed access
YAYu.H. Antypkin
Yu.H. Antypkin
LKL.H. Kyrylova
L.H. Kyrylova
OMO.O. Miroshnykiv
O.O. Miroshnykiv
ODO.O. Dolenko
O.O. Dolenko
VBV.M. Badiuk
V.M. Badiuk
Inborn errors of metabolism (IEM) represent one of the most clinically significant yet underdiagnosed causes of epileptic encephalopathies in young children. The team of the Department of Pediatric Neurology at the State Institution "Ukrainian Center of Maternity and Childhood of the NAMS of Ukraine" has been investigating this problem for over 25 years, which served as the foundation for the preparation of this publication. Particular attention is warranted by pyridoxine-dependent epilepsy (PDE) — a rare autosomal recessive disorder caused by pathogenic variants in the ALDH7A1 gene — as a classical example of a treatable metabolic epileptic encephalopathy. Aim - to systematize current evidence on epileptic encephalopathies in inborn errors of metabolism in young children, and to elucidate the underlying pathogenetic mechanisms, clinical features, and approaches to diagnosis and treatment. A systematic review of the scientific literature was conducted using PubMed/MEDLINE and OMIM databases, with a focus on publications from the past 10 years. A clinical case of a 3-month-old girl with neonatal epilepsy refractory to standard therapy is presented. The diagnostic workup included prolonged video-EEG monitoring, brain MRI, biochemical investigations, and next-generation sequencing (NGS) using the CarrierSeq panel (420 genes). Epileptic seizures associated with IEM are characteristically resistant to standard antiseizure medications and may present as status epilepticus at onset. Age of manifestation serves as a key diagnostic indicator: the neonatal period is most typical for pyridoxine-dependent epilepsy, urea cycle defects, and nonketotic hyperglycinemia, while infancy is more characteristic of GLUT1 deficiency, biotinidase deficiency, and peroxisomal disorders. The diagnostic algorithm encompasses three tiers: a basic biochemical panel (glucose, lactate, pyruvate, ammonia, blood gas analysis, plasma amino acids, urine organic acids, acylcarnitine profile), specialized metabolic tests (α-aminoadipic semialdehyde, pipecolic acid, cerebrospinal fluid pyridoxal phosphate level), and molecular genetic analysis. An empirical therapeutic trial with pyridoxine (30 mg/kg/day for 3 days) is indicated in all neonates with seizures of unknown etiology refractory to conventional therapy. In the presented case, two pathogenic variants in compound heterozygous state were identified in the ALDH7A1 gene, confirming the diagnosis of PDE. Targeted therapy comprising pyridoxine, arginine, folinic acid, and a lysine-restricted diet resulted in sustained seizure remission and normalization of psychomotor development. Conclusions. Early identification and verification of a metabolic defect enables pathogenetically targeted treatment with the potential to fundamentally alter the disease prognosis. Nutritional and vitamin-micronutrient therapy represents an effective therapeutic approach for treatable forms of metabolic epilepsy, particularly in pyridoxine-dependent epilepsies. The authors declare no conflict of interest.

29 December 2024 in INTERNATIONAL NEUROLOGICAL JOURNAL
Verified
Journal Article
Open access
PDF file
LKL.H. Kyrylova
L.H. Kyrylova
OMO.O. Miroshnikov
O.O. Miroshnikov
VKV.I. Kharytonov
V.I. Kharytonov
ODO.O. Dolenko
O.O. Dolenko
VBV.M. Badiuk
V.M. Badiuk
SDS.V. Dyukareva-Bezdenezhnykh
S.V. Dyukareva-Bezdenezhnykh
Background. In modern society, there is a significant increase in the number of neuropsychiatric disorders among children. Modern methods of genetic testing play an important role in diagnosing diseases of the nervous system and neurodevelopmental disorders. The purpose was to analyze the results of genetic studies in children with various neurological disorders and to evaluate their effectiveness in improving diagnostic approaches. Materials and methods. One hundred and sixty children aged 0–18 years (average age 6.7 years) were included in the study. Among them, 131 underwent whole-exome sequencing (WES): 68 (51.9 %) with epilepsy, 31 (23.7 %) with autism spectrum disorders (ASD), and 32 (24.4 %) with neurological disorders. Chromosomal microarray (CMA) was performed in 56 children, including 27 children who underwent both WES and CMA. Results. Among 131 children examined by WES, a positive result was obtained in 59 (45.0 %) cases: 31 patients (45.6 %) with epileptic seizures, 10 children (32.3 %) with ASD, 18 (56.3 %) with neurological disorders. A positive result was obtained by the CMA method in 18 children (32.1 %): 5 (31.3 %) with epilepsy, 11 (30.6 %) with ASD, 2 (50.0 %) with neurological disorders. Among the children exa­mined by CMA, 27 (48.2 %) were previously examined using WES and received a negative result. In this cohort, 8 children (29.6 %) had mutations detected by the CMA method, whereas among children who did not undergo WES, mutations were detected by CMA in 10 cases (34.5 %). Conclusions. WES is the most effective method in neurological disorders (56.3 %) and epilepsy (45.6 % of children). In general, WES showed greater effectiveness in the total sample of children (45.0 %) compared to CMA (32.1 %). CMA showed higher effectiveness in neurological disorders (50.0 %). Among children with a negative WES result, 29.6 % had pathogenic variants detected by CMA. The research was carried out in accordance with the principles of the Declaration of Helsinki. Informed consent for the research was obtained from the patients and their parents. The authors declare no conflict of interest.

7 September 2025 in INTERNATIONAL NEUROLOGICAL JOURNAL
Verified
Journal Article
Open access
YAYu.H. Antypkin
Yu.H. Antypkin
LKL.H. Kyrylova
L.H. Kyrylova
OMO.O. Miroshnikov
O.O. Miroshnikov
ODO.O. Dolenko
O.O. Dolenko
VBV.M. Badiuk
V.M. Badiuk
Background. X-linked creatine transporter deficiency (CTD) is a rare genetic metabolic disorder causing significant neurological impairments. It results from mutations in the SLC6A8 gene, which disrupt creatine transport into the brain. Clinical manifestations include developmental delay, intellectual disability, behavioral disorders, and epilepsy, often complicating early diagnosis. The purpose was to summarize current data on the pathogenesis, diagnosis, and treatment of CTD, and to present a clinical case illustrating the diagnostic challenges in this condition. Materials and methods. This article reviews the pathogenesis of CTD, which stems from a deficit in creatine transport to the brain. Diagnosis relies on clinical presentation, biochemical tests (creatine/urine creatinine ratio), and magnetic resonance spectroscopy (MRS), which reveals an absence of creatine peaks in the brain. The gold standard for diagnosis is molecular genetic testing (whole exome sequencing — WES). We present a clinical case of drug-resistant epilepsy and developmental delay in a boy whose CTD diagnosis was confirmed by WES and MRS. Results. Early diagnosis and timely initiation of therapy are crucial for improving prognosis. While no standardized treatment exists, combination therapy with creatine, L-arginine, and glycine proves more effective than creatine alone, as creatine precursors can utilize alternative pathways of transport into the brain. Promising avenues include the development of lipophilic creatine analogs and chaperone therapy. Conclusions. CTD is a serious condition requiring high awareness among clinicians for timely diagnosis. Combined supplementation with creatine and its precursors is the most evidence-based treatment strategy. Further research into novel therapeutic approaches, such as gene therapy, is vital for future treatment.